{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T02:27:37Z","timestamp":1770776857434,"version":"3.50.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,30]]},"DOI":"10.7759\/cureus.26447","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T13:21:13Z","timestamp":1656595273000},"source":"Crossref","is-referenced-by-count":2,"title":["Gender Trends in Psychotropic Medication Use in Autism"],"prefix":"10.7759","author":[{"given":"Christopher R","family":"Huber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Fanaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Soti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss6904a1","article-title":"Prevalence of autism spectrum disorder among children aged 8 years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016","volume":"69","author":"Maenner MJ","year":"2020","unstructured":"Maenner MJ, Shaw KA, Baio J, et al.. Prevalence of autism spectrum disorder among children aged 8 years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016. MMWR Surveill Summ. 2020, 69:1-12. 10.15585\/mmwr.ss6904a1","journal-title":"MMWR Surveill Summ"},{"key":"ref2","article-title":"Diagnostic and Statistical Manual of Mental Disorders (5th edition text revision)","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th edition text revision). American Psychiatric Publishing, Washington, DC; 2013."},{"key":"ref3","article-title":"Complete guide to Asperger\u2019s syndrome","author":"Attwood T","year":"2007","unstructured":"Attwood T. Complete guide to Asperger\u2019s syndrome. Jessica Kingsley Publishers, Philadelphia, PA; 2007."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2012.14.3\/cdoyle","article-title":"Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan","volume":"14","author":"Doyle CA","year":"2012","unstructured":"Doyle CA, McDougle CJ. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci. 2012, 14:263-79. 10.31887\/DCNS.2012.14.3\/cdoyle","journal-title":"Dialogues Clin Neurosci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12644","article-title":"Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review","volume":"135","author":"Jobski K","year":"2017","unstructured":"Jobski K, H\u00f6fer J, Hoffmann F, Bachmann C. Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. Acta Psychiatr Scand. 2017, 135:8-28. 10.1111\/acps.12644","journal-title":"Acta Psychiatr Scand"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.22374\/1710-6222.24.3.2","article-title":"Increase in psychoactive drug prescriptions in the years following autism spectrum diagnosis: a population-based cohort study","volume":"24","author":"Croteau C","year":"2017","unstructured":"Croteau C, Mottron L, Presse N, Tarride JE, Dorais M, Perreault S. Increase in psychoactive drug prescriptions in the years following autism spectrum diagnosis: a population-based cohort study. J Popul Ther Clin Pharmacol. 2017, 24:e19-32. 10.22374\/1710-6222.24.3.2","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1362361319840229","article-title":"Use, costs, and predictors of psychiatric healthcare services following an autism spectrum diagnosis: population-based cohort study","volume":"23","author":"Croteau C","year":"2019","unstructured":"Croteau C, Mottron L, Dorais M, Tarride JE, Perreault S. Use, costs, and predictors of psychiatric healthcare services following an autism spectrum diagnosis: population-based cohort study. Autism. 2019, 23:2020-30. 10.1177\/1362361319840229","journal-title":"Autism"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2013.0101","article-title":"Gender and injuries predict stimulant medication use","volume":"24","author":"Dalsgaard S","year":"2014","unstructured":"Dalsgaard S, Leckman JF, Nielsen HS, Simonsen M. Gender and injuries predict stimulant medication use. J Child Adolesc Psychopharmacol. 2014, 24:253-9. 10.1089\/cap.2013.0101","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2013.05.028","article-title":"Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany","volume":"34","author":"Bachmann CJ","year":"2013","unstructured":"Bachmann CJ, Manthey T, Kamp-Becker I, Glaeske G, Hoffmann F. Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. Res Dev Disabil. 2013, 34:2551-63. 10.1016\/j.ridd.2013.05.028","journal-title":"Res Dev Disabil"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2011.10.001","article-title":"Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: perspective from a developing country","volume":"33","author":"Memari AH","year":"2012","unstructured":"Memari AH, Ziaee V, Beygi S, Moshayedi P, Mirfazeli FS. Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: perspective from a developing country. Res Dev Disabil. 2012, 33:563-9. 10.1016\/j.ridd.2011.10.001","journal-title":"Res Dev Disabil"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18084120","article-title":"The use of psychotropic medication in Iranian children with developmental disabilities","volume":"18","author":"McConkey R","year":"2021","unstructured":"McConkey R, Samadi SA, Mahmoodizadeh A, Taggart L. The use of psychotropic medication in Iranian children with developmental disabilities. Int J Environ Res Public Health. 2021, 18:4120. 10.3390\/ijerph18084120","journal-title":"Int J Environ Res Public Health"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0092","article-title":"Characteristics associated with drug prescription and compliance among young children with autism spectrum disorder","volume":"28","author":"Meiri G","year":"2018","unstructured":"Meiri G, Azoulay H, Menashe I. Characteristics associated with drug prescription and compliance among young children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2018, 28:232-7. 10.1089\/cap.2017.0092","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.04.013","article-title":"Prevalence and predictors of psychotropic medication use in adolescents and adults with autism spectrum disorder in Italy: a cross-sectional study","volume":"276","author":"Fusar-Poli L","year":"2019","unstructured":"Fusar-Poli L, Brondino N, Rocchetti M, et al.. Prevalence and predictors of psychotropic medication use in adolescents and adults with autism spectrum disorder in Italy: a cross-sectional study. Psychiatry Res. 2019, 276:203-9. 10.1016\/j.psychres.2019.04.013","journal-title":"Psychiatry Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.10.1687","article-title":"Prescription trends of psychotropics in children and adolescents with autism based on Nationwide Health Insurance data","volume":"32","author":"Hong M","year":"2017","unstructured":"Hong M, Lee SY, Han J, et al.. Prescription trends of psychotropics in children and adolescents with autism based on Nationwide Health Insurance data. J Korean Med Sci. 2017, 32:1687-93. 10.3346\/jkms.2017.32.10.1687","journal-title":"J Korean Med Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/aur.2040","article-title":"Psychiatric comorbidities and psychotropic medication use in autism: a matched cohort study with ADHD and general population comparator groups in the United Kingdom","volume":"11","author":"Houghton R","year":"2018","unstructured":"Houghton R, Liu C, Bolognani F. Psychiatric comorbidities and psychotropic medication use in autism: a matched cohort study with ADHD and general population comparator groups in the United Kingdom. Autism Res. 2018, 11:1690-700. 10.1002\/aur.2040","journal-title":"Autism Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-019-04291-8","article-title":"Psychotropic medication prescribing for neuropsychiatric comorbidities in individuals diagnosed with autism spectrum disorder (ASD) in the UK","volume":"50","author":"Alfageh BH","year":"2020","unstructured":"Alfageh BH, Man KK, Besag FM, Alhawassi TM, Wong IC, Brauer R. Psychotropic medication prescribing for neuropsychiatric comorbidities in individuals diagnosed with autism spectrum disorder (ASD) in the UK. J Autism Dev Disord. 2020, 50:625-33. 10.1007\/s10803-019-04291-8","journal-title":"J Autism Dev Disord"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3140-7","article-title":"Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care","volume":"231","author":"Murray ML","year":"2014","unstructured":"Murray ML, Hsia Y, Glaser K, et al.. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology (Berl). 2014, 231:1011-21. 10.1007\/s00213-013-3140-7","journal-title":"Psychopharmacology (Berl)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112937","article-title":"Symptom scores and medication treatment patterns in children with ADHD versus autism","volume":"288","author":"Mayes SD","year":"2020","unstructured":"Mayes SD, Waxmonsky JG, Baweja R, et al.. Symptom scores and medication treatment patterns in children with ADHD versus autism. Psychiatry Res. 2020, 288:112937. 10.1016\/j.psychres.2020.112937","journal-title":"Psychiatry Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-3774","article-title":"Psychotropic medication use and polypharmacy in children with autism spectrum disorders","volume":"132","author":"Spencer D","year":"2013","unstructured":"Spencer D, Marshall J, Post B, et al.. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics. 2013, 132:833-40. 10.1542\/peds.2012-3774","journal-title":"Pediatrics"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-017-3153-x","article-title":"Characterization of medication use in a multicenter sample of pediatric inpatients with autism spectrum disorder","volume":"48","author":"Wink LK","year":"2018","unstructured":"Wink LK, Pedapati EV, Adams R, et al.. Characterization of medication use in a multicenter sample of pediatric inpatients with autism spectrum disorder. J Autism Dev Disord. 2018, 48:3711-9. 10.1007\/s10803-017-3153-x","journal-title":"J Autism Dev Disord"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-0984","article-title":"Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders","volume":"121","author":"Mandell DS","year":"2008","unstructured":"Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008, 121:e441-8. 10.1542\/peds.2007-0984","journal-title":"Pediatrics"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2012.01563.x","article-title":"Use and cost of psychotropic drugs among recipients with autism in a state Medicaid fee-for-service programme","volume":"57","author":"Khanna R","year":"2013","unstructured":"Khanna R, Jariwala K, West-Strum D. Use and cost of psychotropic drugs among recipients with autism in a state Medicaid fee-for-service programme. J Intellect Disabil Res. 2013, 57:161-71. 10.1111\/j.1365-2788.2012.01563.x","journal-title":"J Intellect Disabil Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2017.06.001","article-title":"Autism spectrum disorders and their treatment with psychotropic medications in a nationally representative outpatient sample: 1994-2009","volume":"27","author":"Kamimura-Nishimura K","year":"2017","unstructured":"Kamimura-Nishimura K, Froehlich T, Chirdkiatgumchai V, Adams R, Fredstrom B, Manning P. Autism spectrum disorders and their treatment with psychotropic medications in a nationally representative outpatient sample: 1994-2009. Ann Epidemiol. 2017, 27:448-53.e1. 10.1016\/j.annepidem.2017.06.001","journal-title":"Ann Epidemiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-019-03903-7","article-title":"Psychotropic medication use for adults with autism spectrum disorder who receive services and supports through adult developmental disability services in the United States","volume":"49","author":"Esler A","year":"2019","unstructured":"Esler A, Hewitt A, Hall-Lande J, Pettingell SL, Houseworth J. Psychotropic medication use for adults with autism spectrum disorder who receive services and supports through adult developmental disability services in the United States. J Autism Dev Disord. 2019, 49:2291-303. 10.1007\/s10803-019-03903-7","journal-title":"J Autism Dev Disord"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0057","article-title":"Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit\/hyperactivity disorder","volume":"21","author":"Frazier TW","year":"2011","unstructured":"Frazier TW, Shattuck PT, Narendorf SC, Cooper BP, Wagner M, Spitznagel EL. Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011, 21:571-9. 10.1089\/cap.2011.0057","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-016-2946-7","article-title":"Psychotropic medication use among insured children with autism spectrum disorder","volume":"47","author":"Madden JM","year":"2017","unstructured":"Madden JM, Lakoma MD, Lynch FL, et al.. Psychotropic medication use among insured children with autism spectrum disorder. J Autism Dev Disord. 2017, 47:144-54. 10.1007\/s10803-016-2946-7","journal-title":"J Autism Dev Disord"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0000000000000136","article-title":"Parent health beliefs, social determinants of health, and child health services utilization among U.S. school-age children with autism","volume":"36","author":"Zuckerman KE","year":"2015","unstructured":"Zuckerman KE, Lindly OJ, Sinche BK, Nicolaidis C. Parent health beliefs, social determinants of health, and child health services utilization among U.S. school-age children with autism. J Dev Behav Pediatr. 2015, 36:146-57. 10.1097\/DBP.0000000000000136","journal-title":"J Dev Behav Pediatr"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/aur.1848","article-title":"Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States","volume":"10","author":"Houghton R","year":"2017","unstructured":"Houghton R, Ong RC, Bolognani F. Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States. Autism Res. 2017, 10:2037-47. 10.1002\/aur.1848","journal-title":"Autism Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-0900D","article-title":"Use of psychotropic medication in children and adolescents with autism spectrum disorders","volume":"130 Suppl 2","author":"Coury DL","year":"2012","unstructured":"Coury DL, Anagnostou E, Manning-Courtney P, et al.. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics. 2012, 130 Suppl 2:S69-76. 10.1542\/peds.2012-0900D","journal-title":"Pediatrics"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1895M","article-title":"Therapy and psychotropic medication use in young children with autism spectrum disorder","volume":"145","author":"Ziskind D","year":"2020","unstructured":"Ziskind D, Bennett A, Jawad A, Blum N. Therapy and psychotropic medication use in young children with autism spectrum disorder. Pediatrics. 2020, 145:S99-S107. 10.1542\/peds.2019-1895M","journal-title":"Pediatrics"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2012.06.006","article-title":"Impact of a private health insurance mandate on public sector autism service use in Pennsylvania","volume":"51","author":"Stein BD","year":"2012","unstructured":"Stein BD, Sorbero MJ, Goswami U, Schuster J, Leslie DL. Impact of a private health insurance mandate on public sector autism service use in Pennsylvania. J Am Acad Child Adolesc Psychiatry. 2012, 51:771-9. 10.1016\/j.jaac.2012.06.006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-016-0036-8","article-title":"Prescription trends in children with pervasive developmental disorders: a claims data-based study in Japan","volume":"12","author":"Satoh M","year":"2016","unstructured":"Satoh M, Obara T, Nishigori H, et al.. Prescription trends in children with pervasive developmental disorders: a claims data-based study in Japan. World J Pediatr. 2016, 12:443-9. 10.1007\/s12519-016-0036-8","journal-title":"World J Pediatr"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-017-3058-8","article-title":"Medical conditions and demographic, service and clinical factors associated with atypical antipsychotic medication use among children with an autism spectrum disorder","volume":"47","author":"Lake JK","year":"2017","unstructured":"Lake JK, Denton D, Lunsky Y, Shui AM, Veenstra-VanderWeele J, Anagnostou E. Medical conditions and demographic, service and clinical factors associated with atypical antipsychotic medication use among children with an autism spectrum disorder. J Autism Dev Disord. 2017, 47:1391-402. 10.1007\/s10803-017-3058-8","journal-title":"J Autism Dev Disord"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2021.01.028","article-title":"Melatonin dispensing among New Zealand children aged 0-18 years with autism: a nationwide cross-sectional study","volume":"80","author":"McLay LK","year":"2021","unstructured":"McLay LK, Schluter PJ, Eggleston MJ, Woodford EC, Bowden N. Melatonin dispensing among New Zealand children aged 0-18 years with autism: a nationwide cross-sectional study. Sleep Med. 2021, 80:184-92. 10.1016\/j.sleep.2021.01.028","journal-title":"Sleep Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0039-3","article-title":"A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures","volume":"43","author":"Politte LC","year":"2018","unstructured":"Politte LC, Scahill L, Figueroa J, McCracken JT, King B, McDougle CJ. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology. 2018, 43:1772-8. 10.1038\/s41386-018-0039-3","journal-title":"Neuropsychopharmacology"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.29245\/2578-2959\/2018\/2.1120","article-title":"Pharmacogenetics and psychiatric care: a review and commentary","volume":"2","author":"Butler MG","year":"2018","unstructured":"Butler MG. Pharmacogenetics and psychiatric care: a review and commentary. J Ment Health Clin Psychol. 2018, 2:17-24. 10.29245\/2578-2959\/2018\/2.1120","journal-title":"J Ment Health Clin Psychol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/103240-gender-trends-in-psychotropic-medication-use-in-autism","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:22Z","timestamp":1707508042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/103240-gender-trends-in-psychotropic-medication-use-in-autism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.26447","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}